Stoke Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Stoke Therapeutics

12/08/2025 21:44

Stoke Therapeutics Inc STOK.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -46 cents.  The mean expectation of ten analysts for the quarter was for a loss of 51 cents per share. Wall Street expected results to range from -68 cents to -3 cents per share.

Revenue rose 186% to $13.82 million from a year ago; analysts expected $8.91 million.

Stoke Therapeutics Inc's reported EPS for the quarter was a loss of 40 cents​.

The company reported a quarterly loss of $23.48 million.

Stoke Therapeutics Inc shares had risen by 15.9% this quarter and gained 19.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Stoke Therapeutics Inc is $22.00, about 40.2% above its last closing price of $13.16

This summary was machine generated from LSEG data August 12 at 08:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.51
-0.40
Beat
Mar. 31 2025
-0.42
1.98
Beat
Dec. 31 2024
-0.53
-0.18
Beat
Sep. 30 2024
-0.53
-0.47
Beat